Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 828 of 6351
-
New hope for rare blood disorder: experimental pill reduces need for transfusions
Disease control CompletedBackground: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Bet…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on deadly brain cancer
Disease control Recruiting nowThis is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a pill tame lupus? large trial tests upadacitinib
Disease control OngoingSystemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change …
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a 14-Day drug delay diabetes in toddlers?
Disease control OngoingThe purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to boost immunotherapy success in lung cancer
Disease control CompletedThis prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug pair aims to shrink Hard-to-Treat breast tumors
Disease control Recruiting nowThis clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil …
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
AI reads skin scars to pick best cancer treatment
Knowledge-focused Recruiting nowIn the last decade, the advent of immunotherapies with inhibitors of immune checkpoints, such as anti-PD-1 and anti-CTLA-4, has revolutionized the treatment of advanced or metastatic melanoma. However, the clinical benefit remains limited to a subset of patients. Identifying the …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Game-Based app aims to boost HPV vaccination in young cancer survivors
Prevention OngoingThe primary objectives of this study are to increase HPV vaccination initiation and 3-dose completion among pediatric, adolescent, and young adult (PAYA) cancer survivors
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Virus therapy takes on tough lung cancer
Disease control Recruiting nowOncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Phase 1/2 • Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Searching for biomarkers to combat malnutrition
Knowledge-focused CompletedThe latest data from the World Health Organization (WHO) shows that malnutrition in all its forms affects over 2.5 billion people globally. This condition is constantly increasing and affects the entire population, from childhood to the elderly. Malnutrition in all its forms nega…
Sponsor: Federico II University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Gene therapy watch: RGX-111 safety tracked in MPS i patients
Disease control By invitation onlyRGX-111-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separ…
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New Toxin-Neutralizing drug could speed recovery from severe pneumonia
Disease control OngoingThis is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
Phase 2 • Sponsor: Eagle Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Partici…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited super cells take on childhood leukemia
Disease control OngoingIn this phase 1 clinical trial, the investigators are testing an experimental medicine in children aged 6 months up to 16 years with acute myeloid leukaemia (AML), which has come back (relapsed). The new product is made from white blood cells (T cells) collected from a healthy do…
Phase 1 • Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New targeted drug shows promise for hard-to-treat lung cancer
Disease control OngoingIt is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Phase 2 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Tailored cocktail aims to wipe out CLL in young High-Risk patients
Disease control OngoingMulticentric phase 2 study for previously untreated high-risk CLL patients. Patients will receive 6 courses of the Venetoclax + Obinutuzumab combination. * Patients with stable disease or a response (CR/PR) with uMRD in the PB and BM at cycle 9 will continue treatment with Venet…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill could ease stiffness and pain for ankylosing spondylitis patients
Disease control OngoingThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered t cells take on deadly childhood brain cancer
Disease control Stopped earlyThis phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are HLA-A\*0201-positive and have H3.3K27M-mutated diffuse midline glio…
Phase 1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Village healers join fight against HIV: new study tests Life-Saving support
Disease control Recruiting nowThis study aims to test a new approach to support people living with Human Immunodeficiency Virus (HIV) in Uganda. Traditional healers (TH) will be trained to provide counselling and testing for HIV, help patients start antiretroviral therapy quickly, and offer guidance on taking…
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Spirulina extract put to the test against long COVID inflammation
Disease control CompletedThis is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
Phase 3 • Sponsor: University of Mississippi Medical Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC